Moreover, the overexpression of PER1 and PER2 has been shown to impair tumor proliferation and induce apoptosis in lung, prostate, and pancreatic cancer (29, 62, 63), reinforcing the idea that the molecular clock machinery may be considered as a new therapeutic target. The gene discussed is PER1; the disease is familial pancreatic carcinoma.